Oncolytics Biotech gains as enrollments for GIT cancer trial conclude
Source: SeekingAlpha
2026-02-24 14:45:58 ET
More on Oncolytics Biotech
- Oncolytics Biotech Inc. (ONCY) Shareholder/Analyst Call Prepared Remarks Transcript
- Oncolytics surges on Fast Track status for pelareorep in colorectal cancer
- Oncolytics rises on additional data for pelareorep in colorectal cancer
- Seeking Alpha’s Quant Rating on Oncolytics Biotech
- Historical earnings data for Oncolytics Biotech
Read the full article on Seeking Alpha
For further details see:
Oncolytics Biotech gains as enrollments for GIT cancer trial conclude
Oncolytics Biotech Inc.
NASDAQ: ONCY
ONCY Trading
-3.69% G/L:
$1.045 Last:
931,917 Volume:
$1.042 Open:
ONCY Latest News
March 05, 2026 09:00:00 am
Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types
March 03, 2026 09:00:00 am
Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion
ONCY Stock Data
$91,131,840
106,702,482
13.96%
27
N/A
Biotechnology & Life Sciences
Healthcare
CA
San Diego
